5-year results from the CLL14 study of venetoc... - CLL Support
5-year results from the CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
You need to be a member of this community to see this post.
Read more about...
42 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL
Great news from this long awaited first published phase 2 study reporting the efficacy of this AVO...
Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
Dated 1st September 2019
In a phase III trial of patients with previously untreated CLL...
Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada
* VENCLEXTA® (venetoclax) plus obinutuzumab is the first chemotherapy-free,
fixed-duration...
Related Posts
- VenR in Relapsed CLL: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from MURANO 3 study
- Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
- Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
- Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Phase 2 CLL2-BAAG trial results from the German CLL Study Group
